October is Breast Cancer Awareness Month—a meaningful time to prioritize breast health and revisit the questions that may be holding you back from seeking hormone care.
If you’re navigating perimenopause or menopause, you may wonder: Could the treatment that helps me feel better affect my breast cancer risk?
You deserve a thoughtful answer that considers the specific hormones, when treatment begins, your personal history, and what the evidence actually shows.
At AP Med Spa, our Beautifully Balanced Method™ begins with listening. We make room for both your long-term health and how you feel today.
What the WHI Studied—and Why the Context Matters
Much of the fear surrounding hormone therapy began with the Women’s Health Initiative, or WHI, in 2002.
Its combined hormone trial studied oral conjugated equine estrogens with medroxyprogesterone acetate, a synthetic progestin. At AP Med Spa, we do not prescribe either medication. Our approach uses body-identical formulations, including estradiol and micronized progesterone.
The WHI enrolled women ages 50–79, with an average age of approximately 63—well beyond perimenopause and, for many, more than a decade into postmenopause. This is an important distinction from the women we typically see at AP Med Spa, who often seek care during the menopausal transition as symptoms begin affecting their sleep, well-being, and daily lives.
Some women reach their 60s without needing treatment for disruptive symptoms. Others have experienced symptoms for years without receiving care. Both experiences deserve respect.
The clinical distinction is that beginning hormone therapy well after menopause is different from addressing symptoms during the menopausal transition. Age, time since menopause, and the reason for treatment all belong in the decision.
For many healthy women younger than 60 or within 10 years of menopause onset, the overall benefit-risk balance is favorable for treating bothersome symptoms and preventing bone loss. This timing distinction matters, particularly for cardiovascular and overall treatment risk; it does not guarantee protection against breast cancer.
The Breast Cancer Findings Were Different for Each Regimen
Long-term WHI follow-up found two different outcomes:
- Estrogen plus medroxyprogesterone acetate: Higher breast cancer incidence than placebo.
- Estrogen alone in women with prior hysterectomy: Lower breast cancer incidence and lower breast cancer mortality than placebo.
The estrogen-only trial reported approximately 22% lower breast cancer incidence and 40% lower breast cancer mortality, in relative terms. These findings deserve a place in the conversation.
However, the trials involved different populations. They cannot establish that the synthetic progestin alone caused the increased risk or that every estrogen formulation offers the same protective effect.
Women with a uterus generally need adequate progesterone or another progestogen alongside systemic estrogen to protect the uterine lining. The estrogen-only findings are not a reason to omit that protection.
Why the Type of Hormone Matters
Body-identical estradiol and micronized progesterone have the same molecular structure as hormones your body produces. That distinction is relevant when evaluating treatment, although “bioidentical” does not automatically mean risk-free.
The French E3N study followed more than 80,000 postmenopausal women. Its overall analysis found no statistically significant increase in breast cancer risk with estrogen plus progesterone, while combinations containing several other progestogens were associated with higher risk.
These findings support evaluating formulations individually. Because the study was observational, it does not prove that micronized progesterone prevents breast cancer or establish that longer use carries no risk.
The question becomes more useful when we ask: Which hormones, for which woman, at what dose, and for how long?
Testosterone and Breast Health: Research Worth Discussing
Dr. Rebecca Glaser, a retired breast cancer surgeon and hormone researcher in Ohio, has investigated testosterone’s potential role in breast health.
Her 2019 prospective cohort study followed 1,267 women receiving testosterone implants, either alone or combined with anastrozole, a medication that reduces conversion of testosterone to estrogen.
The study reported approximately 39% lower invasive breast cancer incidence than expected from age-matched population data. A published 15-year update also reported lower incidence than expected.
These findings are encouraging and support further investigation into a potentially protective effect.
They also have important limits. The studies did not randomly assign comparable women to testosterone or placebo. Differences between treated patients and the comparison population could influence the results. Findings from specific implant regimens cannot automatically be applied to creams, other doses, or broader hormone combinations.
Promising evidence deserves discussion. It does not yet establish testosterone or hormone optimization as a proven breast cancer prevention treatment.
The Benefits Deserve Attention, Too
An informed hormone conversation includes potential benefits as well as risks.
For appropriately selected women, menopausal hormone therapy can:
- Reduce hot flashes and night sweats.
- Improve sleep disrupted by these symptoms.
- Treat vaginal symptoms associated with menopause.
- Prevent bone loss and reduce fracture risk.
The right treatment depends on the woman. Formulation, dose, route, duration, and follow-up all matter. Transdermal estrogen may lower blood clot risk compared with oral treatment, but that does not establish lower breast cancer risk.
A Separate Conversation for Breast Cancer Survivors
Women who have experienced breast cancer deserve compassionate, effective symptom care.
However, managing symptoms after breast cancer is different from evaluating the risk of a first diagnosis. Randomized research, including the HABITS trial, found more new breast cancer events among survivors receiving systemic hormone therapy. Careful monitoring alone does not eliminate that concern.
A personal history of breast cancer does not exclude every hormonal option. Low-dose vaginal estrogen may be considered for persistent vaginal or urinary symptoms when nonhormonal treatments have been insufficient. For women taking aromatase inhibitors, that decision should include their oncologist. Local vaginal treatment is distinct from systemic hormone therapy.
Dr. Glaser’s research broadens the discussion, but it does not establish that systemic estrogen, progesterone, or testosterone is safe for every survivor.
Your Health, Your Symptoms, Your Plan
Our approach reflects the individualized hormone care philosophy central to Stacy’s Worldlink Medical training: listen to the woman’s experience, evaluate the specific treatment, and reassess as her needs change.
Through the Beautifully Balanced Method™, we consider your symptoms alongside your personal and family history, breast screening, bone health, cardiovascular factors, and relevant laboratory findings.
We explain established benefits, potential risks, and emerging research. Laboratory results can inform care, but they cannot certify that a treatment is cancer-safe.
This Breast Cancer Awareness Month, give yourself permission to ask questions and explore your options with thoughtful support.
Schedule a Beautifully Balanced Method™ consultation at AP Med Spa in Encinitas to discuss your symptoms, health history, and personalized treatment options.
Because Balance is Beautiful.
AUTHOR BLOCK: Stacy Grissen, MSN, AGNP-C, BSN, RN
